Nasdaq

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

12-05-2026

Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Caroline Munk Esbjerg
2	Reason for the notification
a)	Position/status	Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Shares received as gift
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	50

d)	Aggregated information Aggregated volume Price	50 shares DKK 14,715
e)	Date of the transaction	2026-05-07
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Sofie Munk Esbjerg
2	Reason for the notification
a)	Position/status	Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Shares received as gift
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.25	50

d)	Aggregated information Aggregated volume Price	50 shares DKK 14,712.50
e)	Date of the transaction	2026-05-07
f)	Place of the transaction	Outside a trading venue

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Alex Bruce +45 3444 2613 axeu@novonordisk.com	Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com
Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com	Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com

Company announcement No 31 / 2026

Attachment

CA260512-insider-trading

Latest Health & Supplement Reviews